- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00438269
Pilot Study of the Utility of Empiric Antibiotic Therapy for Suspected ICU-Acquired Infection
Appropriate Antimicrobial Therapy in Critical Care: A Pilot Randomized Controlled Trial
Infection developing in the intensive care unit is a common complication of critical illness, but notoriously difficult to diagnose. A definite diagnosis based on the most reliable tests usually is not possible for at least two days. It is unclear what the optimal management approach should be while awaiting the results of diagnostic tests. In some circumstances, broad spectrum antibiotics are started with a plan to adjust them once the results of cultures are available. Observational studies show that this results in greater antibiotic use, and the risk of superinfection and resistance. In other circumstances, antibiotics may be withheld pending the results of cultures, a strategy that leads to a delay in therapy when cultures are positive, and that may be associated with a worse clinical outcome.
We undertook a randomized pilot study to address the question: "In a critically ill patient for whom clinicians are uncertain whether infection may be present, and in whom potential sites of infection have been managed by removing or changing invasive devices, can a policy of delaying antibiotic treatment until cultures are available reduce the risks of excessive antibiotic use, without increasing the risks associated with delayed therapy?"
Recognizing that the question has not been formally addressed before, and that approaches to clinical management are both widely divergent and passionately held, our pilot study tested the feasibility and acceptability of undertaking a larger trial with sufficient power to determine equivalence.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
We randomized critically ill patients who had been in hospital for at least 72 hours, and in the ICU for at least 24 hours, and who manifested either a temperature >38.5 degrees, or a temperature>38.0 degrees and a white cell count >12,000, and in whom clinicians entertained the possibility of infection as a diagnosis, to either site-specific broad spectrum empiric antibiotics or the corresponding placebo. All patients underwent a comprehensive series of investigations to identify an infectious focus, and all patients had full source control, including changes of central lines and urinary catheters, and change of nasogastric to orogastric tubes.
Patients were maintained in assigned study arm for seven days, or until culture data were available, at which time they were switched to culture-guided narrow spectrum therapy
Type d'étude
Inscription
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- In hospital > 72 hrs and in ICU > 24hrs, and
- Core temperature ≥38.5°C, or temperature ≥ 38.0°C with a WBC>12,000/mm3, or temperature ≤ 36.0°C with a WBC > 12,000/mm3
- Suspicion of infection
Exclusion Criteria:
- Age < 18 years
- Imminent death (within 24 hrs) or withdrawal of aggressive therapy
- Prosthetic heart valve or vascular graft
- Neutropenia (Absolute neutrophil count < 1000/mm3)
- Received > 16 hours of a broad spectrum antibiotic in the last 24 hours (3rd gen cephalosporin, fluoroquinolone, carbapenem, anti-pseudomonal penicillin) or any combination therapy
- History of allergic reaction to both study medications
New physical findings consistent with infection:
- Meningeal signs
- Peritonitis + free air on Abdo x-ray
- Soft tissue infection / cellulitis
- Murmur & suspicion of endocarditis
- Newly available (within past 24 hours) culture results consistent with infection
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
|---|
|
Feasibility: = % of eligible patients who were consented and randomized
|
|
Acceptability: = % of patients in each study arm who were switched to open label therapy prior to culture results
|
Mesures de résultats secondaires
Mesure des résultats |
|---|
|
ICU-free days
|
|
Mortality (14, 30, 90 day)
|
|
Microbial resistance patterns
|
|
Antibiotic-free days
|
|
Change in organ dysfunction (MOD scores)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Mary-Anne W Aarts, MD MSc, University of Toronto
- Chercheur principal: John C Marshall, MD, University of Toronto
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Inflammation
- Attributs de la maladie
- Maladie iatrogène
- Choc
- Changements de température corporelle
- Infections
- Maladie critique
- Fièvre
- Syndrome de réponse inflammatoire systémique
- Infection croisée
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-infectieux
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Inhibiteurs de la topoisomérase II
- Inhibiteurs de la topoisomérase
- Agents antibactériens
- Inhibiteurs des enzymes du cytochrome P-450
- Agents antiprotozoaires
- Agents antiparasitaires
- Inhibiteurs du cytochrome P-450 CYP1A2
- Inhibiteurs de la bêta-lactamase
- Métronidazole
- Ciprofloxacine
- Céfazoline
- Méropénem
- Pipéracilline
- Tazobactam
- Pipéracilline, combinaison de médicaments tazobactam
Autres numéros d'identification d'étude
- AATICC Pilot Study
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .